Stock listing

Ocumension Therapeutics

Selected listing: A2P723 · LS · EUR · DE

Ocumension Therapeutics (Lang & Schwarz: A2P723), Commercial Services. Latest release Aug 12, 2024: OcuMension acquires rights to Alcon eye drops in exchange…

A2P723:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2P723
Asset type: Stock
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Ocumension Therapeutics

OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

August 12, 2024

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

March 21, 2024

Ocumension Therapeutics Announces 2023 Interim Results

August 24, 2023

Ocumension Therapeutics Announces 2022 Annual Results

March 30, 2023

Ocumension Therapeutics : INSIDE INFORMATION NEW DRUG APPLICATION OF OUR CORE PRODUCT OT-401 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

June 21, 2022

All Ocumension Therapeutics news →

Research Ocumension Therapeutics

Ocumension Therapeutics company profile

View the public company page for Ocumension Therapeutics on 6ix.

Ocumension Therapeutics news

Read company news and market updates connected to Ocumension Therapeutics.

Ocumension Therapeutics investor events

Find investor webinars, events, and replay context for Ocumension Therapeutics.